ondasdechoque.org
PT-BR

Female pelvic pain and dyspareunia · Single-group study · 2026

Can shockwave ease pelvic floor muscle pain in women?

In this study of 20 women, pain dropped from about 7 to about 2 out of 10, measured four weeks after four focused shockwave sessions. Scores for pelvic floor, bowel, bladder and prolapse symptoms also went down, by smaller amounts.

Improved over time
women with pelvic floor muscle pain
20
sessions
4
weeks of follow-up after treatment
4

Good to know: Based on clinic records, with no comparison group.

Wu YC, Ding DC BMC Women's Health, 2026 · Read the paper ↗

How this study worked

StartFollow-up20 people
One group was followed over time, without a comparison group. Each dot is one person.

What happened

Pelvic pain

0–10 pain scale (middle value) · start and 4 weeks after treatment

Start4 weeks after treatment

Pain dropped from about 7 to about 2 out of 10 (middle values for the group).
Show the numbers
GroupPeopleStart4 weeks after treatment
Focused shockwave2072

The treatment

Focused shockwave

Focused, 4 sessions

Focused wavesMeet at a focal zone below the skin
Sessions
4
Pulses
2,000 per session · 500 at each of four spots around the vulva
Strength
0.3–0.35mJ/mm² · 4 per second
Numbing
Not mentioned
Device
DUOLITH SD1 T-TOP

Compared with: No comparison group

Settings are what each study used, not a prescription.

Who took part

20 women treated at one clinic for pelvic floor muscle pain confirmed on examination.

Focused shockwave20 people

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Twenty women with pelvic floor myofascial pain diagnosed by standardized pelvic examination, treated at one clinic July 2022–February 2024.

Focused vulvar ESWT20enrolled

Retrospective single-arm pre/post cohort; full four-session protocol required for inclusion.

VAS, 0=no pain and 10=most severe pain1 reported outcome
01
Baseline to 4 weeks after ESWT

Pain intensity (VAS)

VAS, 0=no pain and 10=most severe pain score; IQR reported, not SD

medians
GroupnBaselineFollow-up
Focused vulvar ESWT2072

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Wilcoxon r-0.8796CI 95% -0.8878 to -0.8791p <0.01

Within-person baseline to 4-week post-ESWT change; uncontrolled cohort

1 study · 20 participants in this estimate

-1Equal results 00.1
REPORTED COMPARISON TESTp <0.01

Within-person baseline versus 4-week post-treatment

Wilcoxon signed-rank test

Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −5.0 (IQR 3.0); Wilcoxon effect r=−0.8796 (95% bootstrap CI −0.8878 to −0.8791).

Analysis details and source

Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 3.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.

PFDI-20; source does not state the total score range in the article text1 reported outcome
02
Baseline to 4 weeks after ESWT

Pelvic Floor Disability Inventory-20

PFDI-20; source does not state the total score range in the article text PFDI-20; source does not state the total score range in the article text; median (IQR)

medians
GroupnBaselineFollow-up
Focused vulvar ESWT203326.5

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Wilcoxon r-0.7319CI 95% -0.8582 to -0.5297p <0.01

Within-person baseline to 4-week post-ESWT change; uncontrolled cohort

1 study · 20 participants in this estimate

-1Equal results 00.1
REPORTED COMPARISON TESTp <0.01

Within-person baseline versus 4-week post-treatment

Wilcoxon signed-rank test

Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −5.0 (IQR 9.5); r=−0.7319 (95% bootstrap confidence interval −0.8582 to −0.5297). Change did not uniformly reach MCID benchmarks from other populations.

Analysis details and source

Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 9.5. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.

POPDI-6, score 0–24; higher=worse1 reported outcome
03
Baseline to 4 weeks after ESWT

Pelvic Organ Prolapse Distress Inventory-6 (POPDI-6)

POPDI-6, score 0–24; higher=worse POPDI-6, score 0–24; higher=worse; median (IQR)

medians
GroupnBaselineFollow-up
Focused vulvar ESWT20118

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Wilcoxon r-0.7158CI 95% -0.8176 to -0.5992p <0.01

Within-person baseline to 4-week post-ESWT change; uncontrolled cohort

1 study · 20 participants in this estimate

-0.9Equal results 00.1
REPORTED COMPARISON TESTp <0.01

Within-person baseline versus 4-week post-treatment

Wilcoxon signed-rank test

Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −2.0 (IQR 5.0); r=−0.7158 (95% bootstrap confidence interval −0.8176 to −0.5992). No participants had objective prolapse; symptom scores do not imply anatomical prolapse.

Analysis details and source

Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 5.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.

CRADI-8, score 0–32; higher=worse1 reported outcome
04
Baseline to 4 weeks after ESWT

Colorectal-Anal Distress Inventory-8 (CRADI-8)

CRADI-8, score 0–32; higher=worse CRADI-8, score 0–32; higher=worse; median (IQR)

medians
GroupnBaselineFollow-up
Focused vulvar ESWT201310

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Wilcoxon r-0.5387CI 95% -0.789 to -0.1709p <0.05

Within-person baseline to 4-week post-ESWT change; uncontrolled cohort

1 study · 20 participants in this estimate

-0.9Equal results 00.1
REPORTED COMPARISON TESTp <0.05

Within-person baseline versus 4-week post-treatment

Wilcoxon signed-rank test

Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −1.0 (IQR 4.0); r=−0.5387 (95% bootstrap confidence interval −0.7890 to −0.1709).

Analysis details and source

Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 4.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.

UDI-6, score 0–18; higher=worse1 reported outcome
05
Baseline to 4 weeks after ESWT

Urinary Distress Inventory-6 (UDI-6)

UDI-6, score 0–18; higher=worse UDI-6, score 0–18; higher=worse; median (IQR)

medians
GroupnBaselineFollow-up
Focused vulvar ESWT20109

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Wilcoxon r-0.7014CI 95% -0.8285 to -0.4845p <0.01

Within-person baseline to 4-week post-ESWT change; uncontrolled cohort

1 study · 20 participants in this estimate

-0.9Equal results 00.1
REPORTED COMPARISON TESTp <0.01

Within-person baseline versus 4-week post-treatment

Wilcoxon signed-rank test

Median score decreased after ESWT; lower scores indicate fewer symptoms. This uncontrolled pre/post change does not establish treatment efficacy. Median difference −1.0 (IQR 3.0); r=−0.7014 (95% bootstrap confidence interval −0.8285 to −0.4845).

Analysis details and source

Table 2 reports these as medians (IQR), not SD or quartile bounds. Median difference IQR: 3.0. Timing as printed: the Outcome measures and Follow-up sections say ‘4 weeks after treatment’, but the Abstract and the inclusion paragraph place it after four weeks of ESWT, and the Discussion refers to ‘the four-week ESWT treatment period’. With the Abstract’s once-weekly schedule, this visit may fall at the end of the course rather than four weeks after the last session.

How treatment was delivered
Focused ESWT to bilateral vulvar regions

DUOLITH SD1 T-TOP, F-SW probe; focused treatment perpendicular to upper/lower vulvar regions on both sides. 2,000 hits/session total (500 at each of four regions), EFD 0.3–0.35 mJ/mm², 4 Hz. The Abstract says once weekly for four consecutive weeks, while the Methods say ‘four consecutive treatments per week’; assessments were at baseline and at the 4-week follow-up (‘4 weeks after treatment’ in the Methods; ‘after 4 weeks of ESWT’ in the Abstract). No comparator or co-care is described.

HARMS & TOLERABILITY

Adverse events were collected by patient self-report and the investigator assessed their relation to ESWT (Methods), but the article reports no adverse-event results: no counts, no types and no statement that none occurred.

LIMITS OF THE ANALYSIS

Small retrospective, single-center, uncontrolled cohort (n=20), subjective patient-reported endpoints, unblinded treatment/assessment, four-week follow-up, multiple comparisons without correction, and uncertain diagnostic generalizability. No natural-history or placebo comparison; observed changes may reflect expectation, fluctuation or regression to the mean.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Small retrospective, single-center, uncontrolled cohort (n=20), subjective patient-reported endpoints, unblinded treatment/assessment, four-week follow-up, multiple comparisons without correction, and uncertain diagnostic generalizability. No natural-history or placebo comparison; observed changes may reflect expectation, fluctuation or regression to the mean.
Research review

Source-linked critical reading

Retrospective single-cohort before-after study

Reading depthMaterial consulted
Technical source record

Read article, case definition, treatment details, measurement definitions, raw Tables 1–3 and figure caption, median/IQR outcomes, Wilcoxon effects, limitations and discussion.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design and evidence base

Retrospective single-center cohort of consecutive patients treated July 2022–February 2024; n=20 completed the four-session protocol.

Participants

Women with reproducible pelvic floor muscle tenderness/trigger points and characteristic pain; alternative structural causes excluded.

Intervention

DUOLITH SD1 T-TOP focused F-SW probe, 2,000 hits/session across four bilateral vulvar regions, 0.3–0.35 mJ/mm², 4 Hz; four sessions. Text is ambiguous about exact session spacing.

Comparator

No comparator or co-intervention is described.

Outcomes

Median VAS decreased 7.0 to 2.0; PFDI-20 33.0 to 26.5; POPDI-6 11 to 8; CRADI-8 13 to 10; UDI-6 10 to 9. Wilcoxon p values <0.01, <0.01, <0.01, <0.05 and <0.01, respectively.

Comparative findings

Pre/post effect sizes r ranged −0.5387 to −0.8796. These are within-cohort associations; PFDI changes did not uniformly meet MCID thresholds derived from other populations.

Harms

No detailed ESWT harms table is presented.

Limitations

Small, retrospective, unblinded, uncontrolled n=20, subjective scales, four-week follow-up, multiple uncorrected comparisons, potential expectation/natural fluctuation, and no external control.

Applicability

Findings are preliminary and specific to women meeting this clinic’s PFMP case definition; they do not establish causality or durability.

Research needs

Prospective controlled trials with longer follow-up, clear treatment spacing, prespecified outcomes and harms monitoring are needed.

THE ORIGINAL SOURCE

Read the original article.

Effects of extracorporeal shockwave therapy on pain and pelvic floor function in women with pelvic floor myofascial pain: a retrospective cohort analysis.

Wu YC, Ding DC. · BMC women's health · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →